Trial record 2 of 29 for:
Open Studies | "Adrenal Insufficiency"
The Significance of Defensin Alpha 4 in the Pathophysiology of the Adrenal Insufficiency in Inflammatory Lung Diseases
The recruitment status of this study is unknown because the information has not been verified recently.
Verified October 2012 by Cantonal Hospital of St. Gallen.
Recruitment status was Not yet recruiting
Information provided by (Responsible Party):
Martin BRUTSCHE, Cantonal Hospital of St. Gallen
First received: October 5, 2012
Last updated: October 9, 2012
Last verified: October 2012
The pathophysiology of the adrenal insufficiency of patients with critical diseases remains unclear. In a prior exploratory study investigating patients with exacerbation of chronic obstructive pulmonary disease (COPD), the investigators demonstrated a highly significant correlation between the expression level of Defensin-alpha 4 (DEFA4) mRNA in blood and the adrenal function assessed via low-dose ACTH tests. The aim of this prospective study is to demonstrate that DEFA4 measured both at the mRNA level (RT-PCR) and at the protein level (Western blot/Elisa) is a reliable biomarker for the prediction of adrenal insufficiency in inflammatory lung diseases (patients with COPD and pneumonia).
Inflammatory Lung Diseases
||Observational Model: Cohort
Time Perspective: Prospective
||The Significance of Defensin Alpha 4 in the Pathophysiology of the Adrenal Insufficiency in Inflammatory Lung Diseases
Biospecimen Retention: Samples With DNA
| Estimated Enrollment:
| Study Start Date:
|Ages Eligible for Study:
||18 Years to 80 Years
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
Pneumonia patients (n=30) COPD patients (n=30) Healthy controls (n=15)
- Patients 18-80 yo
- Patients diagnosed with pneumonia or exacerbated COPD
- Healthy controls 18-80yo
- Signed informed consent
- Pregnant or lactating females
- Life threatening severe disease
- Known primary or secondary adrenal insufficiency
- Systemic steroid therapy in the last 8 weeks
- Systemic therapy with opioid
- Systemic therapy with Ketoconazol, Mitotane, Metopyron, Etomidat, Rifampicin
- In healthy controls: relevant respiratory disease or known adrenal insufficiency or indication of infection
- Allergic reaction to ACTH
- Missing informed consent
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
No Contacts or Locations Provided
No publications provided
||Martin BRUTSCHE, Prof., Cantonal Hospital of St. Gallen
History of Changes
|Other Study ID Numbers:
|Study First Received:
||October 5, 2012
||October 9, 2012
||Switzerland: Ethics Committee of the Canton St. Gallen
Keywords provided by Cantonal Hospital of St. Gallen:
Demonstrate that DEFA4 is a reliable biomarker for the prediction of adrenal insufficiency
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on April 16, 2015
Adrenal Gland Diseases
Endocrine System Diseases
Respiratory Tract Diseases